Incyte und MorphoSys melden Eingang der von der Europäischen Kommission erteilten Zulassung für Minjuvi (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von Erwachsenen mit rezidiviertem oder refraktärem diffusem großzelligem...

- Entscheidung der Kommission basiert auf Daten aus der Studie L-MIND zur Prüfung von Minjuvi in Kombination mit Lenalidomid als Behandlung von Patienten mit rezidiviertem oder refraktärem DLBCL -

Related Keywords

Delaware ,United States ,Planegg ,Bayern ,Germany ,Yulia Neugebauer ,Worldcom Myles Clouston ,Incyte ,Europe Minjuvi ,Worldcom Jeanette Bressi ,Incyte Minjuvi ,Worldcom Catalina Loveman ,Morphosys Vermarktungsrechte ,Worldcom Morphosys ,Christine Chiou ,Morphosys ,Janssen Research ,Nasdaq ,Xmab Technology ,Exchange Commission ,Commission Decision Was ,Development For Tafasitamab ,Us Subsidiaries Morphosys Inc ,Practice Research ,Cancer Research Uk ,Morphosys Receipt ,Meet An Urgent Medical ,Morphosys Diagnosed And ,Commission Decision Was Made ,Patients Now ,Chief Executive ,Patients Have ,Jean Paul Kress ,Medical Needs ,Therapy Would ,Studyl Mind ,Effects Shown ,Professor Drc ,Pier Luigi ,University Of Bologna ,New Treatments ,Historical Lack ,The Study ,Secondary Levels ,They Receive ,Name Monjuvi And ,Incyte Minjuvi Marketed ,Medical Professionals ,Infusion Reactions ,Patients Are ,Medical Treatment ,Reactions Have ,Minjuvi Can ,Thrombozytopenie And ,Each Therapiezyklus ,About Incyte ,Further Information ,About Morphosys ,New Arzneimittelkandidaten ,Morphosys Us Inc ,Zukuftsgerichtete Statements ,Release Include ,Expectations With ,These Forward ,Statements Are ,Risks In Terms ,Company And ,Exchange Commission Reports ,Looking Statements ,Morphosys This Communication ,Contained Herein ,Performance Or Achievements ,May Not Have ,Morphosys Explicitly ,Refractory Diffuse Largeb Cell ,Emerging Market ,Original Text ,Worldcom Image ,Ela Zawislak ,New For Repair Businesses Which Can ,Helden ,Xingang ,Urop 228 Ischen ,Commission ,Rteilten ,Zulassung ,Injuvi ,Tafasitamab ,Combination ,Enalidomid ,Ehandlung ,Rwachsenen ,Ezidiviertem ,Oder ,Efrakt 228 Rem ,Iffusem , ,